Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension
Provided By GlobeNewswire
Last update: Sep 25, 2024
– On track to announce topline data in Q1 2025 –
– Virtual KOL event scheduled on October 30th to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical program for lorundrostat in hypertension –
Read more at globenewswire.com10.52
-0.02 (-0.19%)
Find more stocks in the Stock Screener
MLYS Latest News and Analysis
2 days ago - ChartmillWhich stocks are moving after the closing bell on Friday?Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics.
